Increase in awareness regarding Alzheimer’s disease is a major factor driving the global Alzheimer's drugs market size. Alzheimer’s drugs or Alzheimer's therapies help slow down memory loss. They also help carry out routine activities.
Alzheimer’s drugs are not known to cure the disease in entirety, but can delay the dependency of patients on caregivers.
Advancements in diagnosis and treatment of Alzheimer’s disease is also fueling Alzheimer’s drugs market growth. Manufacturers of Alzheimer's drugs are engaged in discovery and development of innovative drugs that slow down cognitive or functional decline in early-stage phases of the disease.
In line with the latest Alzheimer’s drugs market trends, leading players are striving to introduce highly effective cognitive health solutions and memory-related therapeutics to meet the rising demand across the world.
Alzheimer’s disease is a brain disorder that is characterized by alterations in the brain, which can result in deposition of certain proteins. The disease causes the brain to shrink. It ultimately leads in death of the brain cells.
Alzheimer’s disease is one of the most common causes of dementia, i.e. a gradual declination of memory, thinking, and social skills.
Regulatory bodies such as the U.S. FDA have approved several prescription drugs for Alzheimer’s disease in order to manage the symptoms. Majority of these drugs are suitable for people at middle or early stages of Alzheimer’s.
Currently, there are no known medications to eliminate Alzheimer’s, but a preclinical study conducted by the Penn Medicine researchers states that injection of 4-phenylbutyrate (PBA) resists accumulation of proteins in the brain.
Rivastigmine, galantamine, and donepezil are the cholinesterase inhibitors prescribed for moderate/mild Alzheimer’s symptoms. They help reduce or exercise control over certain behavioral and cognitive symptoms.
Healthcare personnel usually begin with low drug doses. They increase dosage based on the way a patient is able to tolerate it. There have been instances of some people benefiting from higher doses of Alzheimer’s drugs.
However, the possibility of side-effects such as loss of appetite, nausea, headaches, and dizziness due to the heavy intake of medicines cannot be ruled out.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
There has been a marked increase in awareness related to Alzheimer’s disease worldwide, with increasing number of people seeking medical intervention.
Healthcare agencies regularly conduct awareness campaigns regarding the disease. For instance, the Alzheimer’s Association Oklahoma Chapter provides educational training to help recognize the signs of Alzheimer’s disease.
It also connects patients to various community resources to help them obtain information, support, and advice related to the disease.
Alzheimer’s & Brain Awareness Month (June) is a healthcare event organized every year with the objective of raising public awareness about the disease and its eventual impact on the person, family, and the community at large.
The awareness month emphasizes the importance of early diagnosis with an aim to appeal private organizations and local authorities to provide funds in order to continue with research regarding medications.
The Alzheimer’s Association, as part of this initiative, encourages patients to put on a purple ribbon as a mark of battling Alzheimer’s disease, thereby extending support to those affected by the disease.
Governments of various countries are also providing funds to conduct research regarding neurodegenerative medications. For instance, in March 2023, Mayo Clinic received a federal funding of US$ 41.0 Mn for research pertaining to Alzheimer’s disease.
The research program aims to identify the next generation of precision medicine biomarkers with potential new therapeutic targets for Alzheimer’s disease and other diseases related to memory loss.
Thus, rise in awareness campaigns coupled with supportive government funding for research related to cognitive health solutions is boosting Alzheimer's drugs industry growth.
Researchers, in the wake of increasing patient population of Alzheimer’s disease, are focusing on launching innovative devices and therapies for better diagnosis and treatment of the disease.
Latest technologies such as Virtual Reality, AI, and ML are being used to expedite clinical trials and analyze the data obtained. Researchers are able to develop algorithms using AI and ML to analyze larger datasets that could be used for clinical trials of Alzheimer’s.
According to medRxiv, a medical journal, in November 2021, researchers deployed an AI-based approach to interpret the relationship of digital measures (DMs) with questionnaire-based cognition as well as functional activities.
The Support Vector Machine (SVM) helps study magnetic resonance images of brain structures. Logistic regression and decision tree, along with SVM, help study the longitudinal MRI image. Several such ML tools are facilitating quicker diagnosis of the Alzheimer’s disease.
As per Alzheimer’s Disease International, 78 million individuals across the globe are likely to suffer from dementia by 2030. It further states that a case of dementia is registered every three seconds worldwide.
Need for speedy diagnosis of Alzheimer’s disease is necessitating the demand for advanced technologies. This, in turn, is boosting the Alzheimer's drugs market.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest Alzheimer’s drugs market analysis, North America constituted significant share of the global landscape in 2023. The region is expected to continue with its dominance during the forecast period.
Market development in North America can be ascribed to the rise in prevalence of Alzheimer’s disease in the U.S. and Canada and speedy approvals of drugs by regulatory authorities in the region.
In February 2023, Health Canada accepted a new drug submission (NDS) for Lecanemab from Eisai Co., Ltd. & Biogen Inc. as one of the courses of treatment for those suffering from early stage Alzheimer’s.
Alzheimer's drugs market share of Europe has been rising steadily since the last few years owing to efforts made by governments to enhance quality of healthcare and raise awareness about Alzheimer’s disease.
Asia Pacific also recorded substantial market expansion in 2023 owing to the rise in awareness programs undertaken by governments regarding importance of mental health and early diagnosis of ailments such as Alzheimer’s disease.
Companies in Alzheimer's drugs landscape are launching new products and striving to obtain quick approval from regulatory bodies in order to strengthen their industry position.
In March 2022, Corium Inc.’s Adlarity (donepezil hydrochloride), a cholinesterase inhibitor, was approved by the U.S. FDA to treat patients suffering from mild, moderate, severe dementia of Alzheimer’s category.
Allergan plc, Novartis AG, Eisai Co. Ltd., Johnson & Johnson, Daiichi Sankyo Company Limited, Ono Pharmaceutical Co. Ltd., H Lundbeck A/S, and Merz Holding GmbH & Co. KG are the leading players operating in the global Alzheimer’s drugs market.
These companies have been profiled in the Alzheimer's drugs market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 4.0 Bn |
| Market Forecast (Value) in 2034 | US$ 11.6 Bn |
| Growth Rate (CAGR) | 10.0% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 4.0 Bn in 2023
It is projected to grow at a CAGR of 10.0% from 2024 to 2034
Rise in awareness about Alzheimer’s disease and government funding, and advancements in diagnosis and treatment of Alzheimer’s disease
The hospital pharmacies segment accounted for the largest share in 2023
North America was the dominant region in in 2023
Allergan plc, Novartis AG, Eisai Co. Ltd., Johnson & Johnson, Daiichi Sankyo Company Limited, Ono Pharmaceutical Co. Ltd., H Lundbeck A/S, and Merz Holding GmbH & Co. KG
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Alzheimer’s Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Technology, Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Alzheimer’s Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Technology, /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Alzheimer’s Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Cholinergic
6.3.2. Memantine
6.3.3. Combined Drugs
6.3.4. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Alzheimer’s Drugs Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2020-2034
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Sales
7.4. Market Attractiveness Analysis, by Application
8. Global Alzheimer’s Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2020-2034
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Alzheimer’s Drugs Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Drug Class, 2020-2034
9.3.1. Cholinergic
9.3.2. Memantine
9.3.3. Combined Drugs
9.3.4. Others
9.4. Market Value Forecast, by Distribution Channel, 2020-2034
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Sales
9.5. Market Value Forecast, by Country, 2020-2034
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class,
9.6.2. By Distribution Channel
9.6.3. By Country
10. Europe Alzheimer’s Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2020-2034
10.3.1. Cholinergic
10.3.2. Memantine
10.3.3. Combined Drugs
10.3.4. Others
10.4. Market Value Forecast, by Distribution Channel, 2020-2034
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Sales
10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Distribution Channel
10.6.3. By Country/Sub-region
11. Asia Pacific Alzheimer’s Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2020-2034
11.3.1. Cholinergic
11.3.2. Memantine
11.3.3. Combined Drugs
11.3.4. Others
11.4. Market Value Forecast, by Distribution Channel, 2020-2034
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Sales
11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class,
11.6.2. By Distribution Channel
11.6.3. By Country/Sub-region
12. Latin America Alzheimer’s Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2020-2034
12.3.1. Cholinergic
12.3.2. Memantine
12.3.3. Combined Drugs
12.3.4. Others
12.4. Market Value Forecast, by Distribution Channel, 2020-2034
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Sales
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class,
12.6.2. By Distribution Channel
12.6.3. By Country/Sub-region
13. Middle East & Africa Alzheimer’s Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2020-2034
13.3.1. Cholinergic
13.3.2. Memantine
13.3.3. Combined Drugs
13.3.4. Others
13.4. Market Value Forecast, by Distribution Channel, 2020-2034
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Sales
13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class,
13.6.2. By Distribution Channel
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2023)
14.3. Company Profiles
14.3.1. Allergan plc
14.3.1.1. Company Overview
14.3.1.2. Technology, Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Novartis AG
14.3.2.1. Company Overview
14.3.2.2. Technology, Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Eisai Co. Ltd.
14.3.3.1. Company Overview
14.3.3.2. Technology, Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Johnson & Johnson
14.3.4.1. Company Overview
14.3.4.2. Technology, Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Daiichi Sankyo Company Limited
14.3.5.1. Company Overview
14.3.5.2. Technology, Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Ono Pharmaceutical Co. Ltd.
14.3.6.1. Company Overview
14.3.6.2. Technology, Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. H Lundbeck A/S
14.3.7.1. Company Overview
14.3.7.2. Technology, Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Merz Holding GmbH & Co. KG
14.3.8.1. Company Overview
14.3.8.2. Technology, Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
List of Tables
Table 01: Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 02: Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 03: Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Region, 2020-2034
Table 04: North America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country, 2020-2034
Table 05: North America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 06: North America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 07: Europe Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 08: Europe Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 09: Europe Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 10: Asia Pacific Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 11: Asia Pacific Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 12: Asia Pacific Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 13: Latin America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Latin America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 15: Latin America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 16: Middle East & Africa Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Middle East & Africa Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 18: Middle East & Africa Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Alzheimer’s Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Alzheimer’s Drugs Market Revenue (US$ Mn), by Drug Class, 2023
Figure 03: Alzheimer’s Drugs Market Value Share, by Drug Class, 2023
Figure 04: Alzheimer’s Drugs Market Revenue (US$ Mn), by Distribution Channel, 2023
Figure 05: Alzheimer’s Drugs Market Value Share, by Distribution Channel, 2023
Figure 06: Alzheimer’s Drugs Market Value Share, by Region, 2023
Figure 07: Alzheimer’s Drugs Market Value (US$ Mn) Forecast, 2020-2034
Figure 08: Alzheimer’s Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 09: Alzheimer’s Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 10: Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 11: Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 12: Alzheimer’s Drugs Market Value Share Analysis, by Region, 2023 and 2034
Figure 13: Alzheimer’s Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 14: North America Alzheimer’s Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 15: North America Alzheimer’s Drugs Market Attractiveness Analysis, by Country, 2024-2034
Figure 16: North America Alzheimer’s Drugs Market Value Share Analysis, by Country, 2023 and 2034
Figure 17: North America Alzheimer’s Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 18: North America Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 19: North America Alzheimer’s Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 20: North America Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 21: Europe Alzheimer’s Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 22: Europe Alzheimer’s Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 23: Europe Alzheimer’s Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 24: Europe Alzheimer’s Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 25: Europe Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 26: Europe Alzheimer’s Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 27: Europe Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 28: Asia Pacific Alzheimer’s Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 29: Asia Pacific Alzheimer’s Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 30: Asia Pacific Alzheimer’s Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 31: Asia Pacific Alzheimer’s Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 32: Asia Pacific Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 33: Asia Pacific Alzheimer’s Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Asia Pacific Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 35: Latin America Alzheimer’s Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 36: Latin America Alzheimer’s Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 37: Latin America Alzheimer’s Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 38: Latin America Alzheimer’s Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 39: Latin America Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 40: Latin America Alzheimer’s Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 41: Latin America Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 42: Middle East & Africa Alzheimer’s Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 43: Middle East & Africa Alzheimer’s Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 44: Middle East & Africa Alzheimer’s Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 45: Middle East & Africa Alzheimer’s Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 46: Middle East & Africa Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 47: Middle East & Africa Alzheimer’s Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 48: Middle East & Africa Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Alzheimer’s Drugs Market
*86 figures and 60 tables includes